# HRD

1 EU-approved indication of 1 drug needs a HRD result, in 1 tumour type, most of them in ovarian cancer.

## Approved indications by tumour

### Ovarian cancer

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Olaparib](https://oncolabels.com/drugs/olaparib) (Lynparza) | HRD-positive (BRCA1/2 mutation and/or genomic instability) | + bevacizumab | Maintenance, advanced | High-grade only; In complete or partial response following completion of first-line platinum-based chemotherapy in combination with bevacizumab |

## Label wording

- **Olaparib** (Lynparza), Ovarian cancer, maintenance, advanced: “maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/hrd